SPRY
ARS Pharmaceuticals, Inc.
Price Chart
No historical data available
Latest Quote
$6.07
+0.18 (+3.06%)
Current Price
| Previous Close | $5.89 |
| Open | $5.83 |
| Day High | $6.09 |
| Day Low | $5.62 |
| Volume | 1,272,225 |
Stock Information
| Shares Outstanding | 99.45M |
| Total Debt | $171.60M |
| Cash Equivalents | $143.84M |
| Revenue | $116.93M |
| Net Income | $-215.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $603.65M |
| EPS (TTM) | $-2.18 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $624.44M |
| Sales | $116.93M |
| Income | $-215.43M |
| Book/sh | $0.13 |
| Cash/sh | $1.45 |
| Employees | 195 |
Financial Ratios
| Quick Ratio | 3.15 |
| Current Ratio | 3.48 |
| Debt/Eq | 1371.51 |
Returns & Margins
| ROA | -48.02% |
| ROE | -210.35% |
| Gross Margin | 58.35% |
| Operating Margin | -182.62% |
| Profit Margin | -184.24% |
Ownership
| Insider Ownership | 16.18% |
| Institutional Ownership | 92.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.74 |
| P/S | 5.10 |
| P/B | 47.62 |
Analyst Data
| Recommendation | none |
| Target Price | $23.25 |
Technical Indicators
| SMA20 | $5.85 |
| SMA50 | $6.79 |
| SMA200 | $8.61 |
| RSI | 50.76 |
| ATR | 0.4339 |
| Shares Float | 48.03M |
| Short Float | 33.28% |
| Short Ratio | 9.40 |
| Volatility | 0.97 |
| Rel Volume | 1.07 |
Performance History
| Week | +12.15% |
| Month | +16.96% |
| Quarter | -36.37% |
| 6 Months | -34.57% |
| YTD | -47.78% |
| Year | -53.34% |
| 3 Years | -13.04% |
| 5 Years | -78.28% |
| 10 Years | -76.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
đ° Latest News
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
Insider Monkey âĸ 2026-08-21T22:08:32Z
Can ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?
Zacks âĸ 2026-08-20T13:55:02Z
ARS Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby âĸ 2026-08-14T12:30:00Z
ARS Pharmaceuticals Inc (SPRY) (Q2 2026) Earnings Call Highlights: Market Share Doubles to 5% ...
GuruFocus.com âĸ 2026-08-14T05:02:20ZARS Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat âĸ 2026-08-14T03:04:04Z
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
Zacks âĸ 2026-08-13T21:35:03Z
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Zacks âĸ 2026-08-06T13:50:13Z
ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO
Insider Monkey âĸ 2026-07-15T15:42:59Z
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
Zacks âĸ 2026-07-08T06:52:00Z
ARS Pharmaceuticals (SPRY) Is Down 11.5% After Losing Spots in Key Russell 2000 Defensive Indices
Simply Wall St. âĸ 2026-06-29T02:06:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $20,423,000 | $977,000 | $0 | - |
| Cost Of Revenue | $20,423,000 | $977,000 | $0 | - |
| Total Revenue | $84,278,000 | $89,149,000 | $30,000 | $1,316,000 |
| Operating Revenue | $84,278,000 | $89,149,000 | $30,000 | $1,316,000 |
| Expenses | ||||
| Interest Expense | $2,599,000 | $0 | - | - |
| Total Expenses | $263,726,000 | $92,232,000 | $67,550,000 | $36,832,000 |
| Net Non Operating Interest Income Expense | $8,070,000 | $11,369,000 | - | - |
| Interest Expense Non Operating | $2,599,000 | $0 | - | - |
| Operating Expense | $243,303,000 | $91,255,000 | $67,550,000 | $36,832,000 |
| Other Income Expense | - | $11,369,000 | $13,155,000 | $834,000 |
| Other Non Operating Income Expenses | - | $11,369,000 | $13,155,000 | $974,000 |
| General And Administrative Expense | - | - | $47,284,000 | $18,456,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Net Interest Income | $8,070,000 | $11,369,000 | - | - |
| Interest Income | $10,669,000 | $11,369,000 | - | - |
| Normalized Income | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,542,000 |
| Net Income From Continuing And Discontinued Operation | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Total Operating Income As Reported | $-179,448,000 | $-3,083,000 | $-67,520,000 | $-35,516,000 |
| Net Income Common Stockholders | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Net Income | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Net Income Including Noncontrolling Interests | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Net Income Continuous Operations | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Pretax Income | $-171,378,000 | $8,286,000 | $-54,365,000 | $-34,682,000 |
| Interest Income Non Operating | $10,669,000 | $11,369,000 | - | - |
| Operating Income | $-179,448,000 | $-3,083,000 | $-67,520,000 | $-35,516,000 |
| Gross Profit | $63,855,000 | $88,172,000 | $30,000 | - |
| Per Share | ||||
| Diluted EPS | $-1.74 | $0.08 | $-0.57 | $-0.87 |
| Basic EPS | $-1.74 | $0.08 | $-0.57 | $-0.87 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-168,779,000 | $8,286,000 | $-67,520,000 | $-35,057,000 |
| Reconciled Depreciation | $-4,156,000 | $-7,175,000 | $-6,775,000 | $319,000 |
| EBITDA (Bullshit earnings) | $-168,779,000 | $8,286,000 | $-67,520,000 | $-35,197,000 |
| EBIT | $-168,779,000 | $8,286,000 | $-67,520,000 | $-35,516,000 |
| Diluted Average Shares | $98,566,481 | $102,390,828 | $95,215,322 | $39,956,043 |
| Basic Average Shares | $98,566,481 | $96,936,661 | $95,215,322 | $39,956,043 |
| Diluted NI Availto Com Stockholders | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Tax Provision | $-80,000 | $288,000 | $0 | - |
| Research And Development | $13,181,000 | $19,580,000 | $20,266,000 | $18,376,000 |
| Selling General And Administration | $230,122,000 | $71,675,000 | $47,284,000 | $18,456,000 |
| Other Gand A | - | - | $47,284,000 | $18,456,000 |
| Total Unusual Items | - | - | - | $-140,000 |
| Total Unusual Items Excluding Goodwill | - | - | - | $-140,000 |
| Gain On Sale Of Security | - | - | - | $-140,000 |
Fetched: 2026-08-29
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $99,806,000 | $249,427,000 | $230,143,000 | $272,886,000 |
| Total Assets | $327,652,000 | $351,153,000 | $233,188,000 | $281,435,000 |
| Total Non Current Assets | $42,756,000 | $16,858,000 | $1,462,000 | $3,735,000 |
| Other Non Current Assets | $25,839,000 | $8,421,000 | - | $2,961,000 |
| Goodwill And Other Intangible Assets | $14,452,000 | $7,371,000 | $617,000 | $0 |
| Other Intangible Assets | $14,452,000 | $7,371,000 | $617,000 | - |
| Current Assets | $284,896,000 | $334,295,000 | $231,726,000 | $277,700,000 |
| Prepaid Assets | $6,194,000 | $6,886,000 | $2,028,000 | $2,310,000 |
| Inventory | $8,369,000 | $5,212,000 | $0 | - |
| Receivables | $25,347,000 | $8,175,000 | $686,000 | $1,009,000 |
| Accounts Receivable | $25,347,000 | $8,175,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $244,986,000 | $314,022,000 | $228,360,000 | $274,381,000 |
| Cash And Cash Equivalents | $41,317,000 | $50,817,000 | $70,971,000 | $210,518,000 |
| Non Current Prepaid Assets | - | $2,800,000 | $21,000 | $2,961,000 |
| Other Current Assets | - | $1,232,000 | $652,000 | - |
| Accrued Interest Receivable | - | $987,000 | $686,000 | $796,000 |
| Other Receivables | - | - | $109,000 | $213,000 |
| Debt | ||||
| Net Debt | $55,057,000 | - | - | - |
| Total Debt | $96,374,000 | $42,000 | $274,000 | $481,000 |
| Long Term Debt And Capital Lease Obligation | $96,374,000 | $0 | $37,000 | $251,000 |
| Long Term Debt | $96,374,000 | - | - | - |
| Current Debt And Capital Lease Obligation | - | $42,000 | $237,000 | $230,000 |
| Current Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $213,394,000 | $94,355,000 | $2,428,000 | $8,549,000 |
| Total Non Current Liabilities Net Minority Interest | $174,249,000 | $70,915,000 | $37,000 | $3,105,000 |
| Other Non Current Liabilities | $72,140,000 | $69,383,000 | - | - |
| Non Current Deferred Liabilities | $1,130,000 | $1,532,000 | $0 | $2,854,000 |
| Current Liabilities | $39,145,000 | $23,440,000 | $2,391,000 | $5,444,000 |
| Other Current Liabilities | $588,000 | $42,000 | - | - |
| Current Deferred Liabilities | $609,000 | $557,000 | $0 | $283,000 |
| Payables And Accrued Expenses | $37,948,000 | $22,841,000 | $1,839,000 | $4,484,000 |
| Payables | $5,725,000 | $9,870,000 | $759,000 | $1,833,000 |
| Accounts Payable | $5,725,000 | $9,870,000 | $759,000 | $1,659,000 |
| Other Payable | - | - | $155,000 | $1,001,000 |
| Total Tax Payable | - | - | $4,000 | $174,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $114,258,000 | $256,798,000 | $230,760,000 | $272,886,000 |
| Total Equity Gross Minority Interest | $114,258,000 | $256,798,000 | $230,760,000 | $272,886,000 |
| Stockholders Equity | $114,258,000 | $256,798,000 | $230,760,000 | $272,886,000 |
| Gains Losses Not Affecting Retained Earnings | $125,000 | $220,000 | $49,000 | $407,000 |
| Other Equity Adjustments | $125,000 | $220,000 | $49,000 | $407,000 |
| Retained Earnings | $-294,603,000 | $-123,305,000 | $-131,303,000 | $-76,938,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $99,290,926 | $97,954,172 | $96,414,963 | $93,943,316 |
| Share Issued | $99,290,926 | $97,954,172 | $96,414,963 | $93,943,316 |
| Tangible Book Value | $99,806,000 | $249,427,000 | $230,143,000 | $272,886,000 |
| Invested Capital | $210,632,000 | $256,798,000 | $230,760,000 | $272,886,000 |
| Working Capital | $245,751,000 | $310,855,000 | $229,335,000 | $272,256,000 |
| Total Capitalization | $210,632,000 | $256,798,000 | $230,760,000 | $272,886,000 |
| Additional Paid In Capital | $408,726,000 | $379,873,000 | $362,004,000 | $349,408,000 |
| Capital Stock | $10,000 | $10,000 | $10,000 | $9,000 |
| Common Stock | $10,000 | $10,000 | $10,000 | $9,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Accrued Expenses | $4,605,000 | $0 | - | - |
| Non Current Deferred Revenue | $1,130,000 | $1,532,000 | $0 | $2,854,000 |
| Current Deferred Revenue | $609,000 | $557,000 | $0 | $283,000 |
| Current Accrued Expenses | $32,223,000 | $12,971,000 | $1,080,000 | $2,651,000 |
| Net PPE | $2,465,000 | $1,066,000 | $824,000 | $774,000 |
| Other Short Term Investments | $203,669,000 | $263,205,000 | $157,389,000 | $63,863,000 |
| Capital Lease Obligations | - | $42,000 | $274,000 | $481,000 |
| Long Term Capital Lease Obligation | - | $0 | $37,000 | $251,000 |
| Current Capital Lease Obligation | - | $42,000 | $237,000 | $230,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | $2,293,000 | $315,000 | $447,000 |
| Accumulated Depreciation | - | $-200,000 | $-121,000 | $-48,000 |
| Gross PPE | - | $1,266,000 | $945,000 | $822,000 |
| Leases | - | $24,000 | $24,000 | - |
| Other Properties | - | $987,000 | $840,000 | $822,000 |
| Machinery Furniture Equipment | - | $255,000 | $81,000 | - |
| Properties | - | $0 | $0 | - |
| Finished Goods | - | $5,212,000 | $0 | - |
Fetched: 2026-08-29
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-171,205,000 | $12,985,000 | $-59,441,000 | $-40,277,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-170,866,000 | $13,548,000 | $-59,266,000 | $-40,078,000 |
| Cash Flow From Continuing Operating Activities | $-170,866,000 | $13,548,000 | $-59,266,000 | $-40,078,000 |
| Operating Gains Losses | - | - | - | $140,000 |
| Investing Activities | ||||
| Capital Expenditure | $-339,000 | $-563,000 | $-175,000 | $-199,000 |
| Investing Cash Flow | $56,768,000 | $-106,101,000 | $-87,180,000 | $-199,000 |
| Cash Flow From Continuing Investing Activities | $56,768,000 | $-106,101,000 | $-87,180,000 | $-199,000 |
| Net Other Investing Changes | $-7,860,000 | $-7,500,000 | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $104,598,000 | $72,399,000 | $6,899,000 | $190,732,000 |
| Cash Flow From Continuing Financing Activities | $104,598,000 | $72,399,000 | $6,899,000 | $190,732,000 |
| Net Other Financing Charges | $2,660,000 | $69,383,000 | - | $198,843,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Issuance Of Debt | $96,257,000 | $0 | - | - |
| Interest Paid Supplemental Data | $2,452,000 | $0 | $0 | $366,000 |
| End Cash Position | $41,317,000 | $50,817,000 | $70,971,000 | $210,518,000 |
| Beginning Cash Position | $50,817,000 | $70,971,000 | $210,518,000 | $60,063,000 |
| Changes In Cash | $-9,500,000 | $-20,154,000 | $-139,547,000 | $150,455,000 |
| Proceeds From Stock Option Exercised | $5,681,000 | $3,016,000 | $6,899,000 | $570,000 |
| Net Issuance Payments Of Debt | $96,257,000 | $0 | $0 | $-8,681,000 |
| Net Long Term Debt Issuance | $96,257,000 | $0 | $0 | $-8,681,000 |
| Long Term Debt Issuance | $96,257,000 | $0 | - | - |
| Net Investment Purchase And Sale | $64,967,000 | $-98,038,000 | $-87,005,000 | $0 |
| Sale Of Investment | $307,000,000 | $258,000,000 | $185,000,000 | $0 |
| Purchase Of Investment | $-242,033,000 | $-356,038,000 | $-272,005,000 | $0 |
| Net PPE Purchase And Sale | $-339,000 | $-563,000 | $-175,000 | $-199,000 |
| Purchase Of PPE | $-339,000 | $-563,000 | $-175,000 | $-199,000 |
| Change In Working Capital | $-20,004,000 | $-1,809,000 | $-7,361,000 | $-12,754,000 |
| Change In Other Working Capital | $-350,000 | $2,089,000 | $-3,149,000 | $-1,283,000 |
| Change In Payables And Accrued Expense | $18,881,000 | $16,413,000 | $-2,777,000 | $-10,285,000 |
| Change In Prepaid Assets | $656,000 | $-6,191,000 | $-1,435,000 | $-1,186,000 |
| Change In Inventory | $-21,986,000 | $-5,945,000 | $0 | - |
| Change In Receivables | $-17,205,000 | $-8,175,000 | $0 | - |
| Changes In Account Receivables | $-17,205,000 | $-8,175,000 | $0 | - |
| Other Non Cash Items | $337,000 | - | - | $1,056,000 |
| Stock Based Compensation | $22,095,000 | $14,534,000 | $9,235,000 | $5,843,000 |
| Provisionand Write Offof Assets | $2,160,000 | $0 | - | - |
| Depreciation Amortization Depletion | $-4,156,000 | $-7,175,000 | $-6,775,000 | $319,000 |
| Depreciation And Amortization | $-4,156,000 | $-7,175,000 | $-6,775,000 | $319,000 |
| Amortization Cash Flow | $-5,523,000 | $-7,254,000 | $-6,848,000 | $285,000 |
| Amortization Of Intangibles | $-5,523,000 | $-7,254,000 | $-6,848,000 | $285,000 |
| Depreciation | $1,367,000 | $79,000 | $73,000 | $34,000 |
| Net Income From Continuing Operations | $-171,298,000 | $7,998,000 | $-54,365,000 | $-34,682,000 |
| Repayment Of Debt | - | - | $0 | $-8,681,000 |
| Long Term Debt Payments | - | - | $0 | $-8,681,000 |
| Gain Loss On Investment Securities | - | - | - | $140,000 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-08-29